# Exploring CB1 Autophagy and Obesity in p62-Deficient Mice > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-metabolic-regulation-cb1-autophagy-obesity/ > **Published:** 2026-04-20T18:09:10-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:55:34-04:00 > **Clinical Summary:** Discover how endocannabinoid system metabolic regulation via CB1 autophagy impacts obesity phenotypes in p62-deficient mice in this preclinical study. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic MetabolismCb1ObesityPreclinicalEndocannabinoid Journal Biochemistry and biophysics reports Study Type Clinical Study Population Human participants Why This Matters This preclinical study elucidates how CB1 receptors are regulated through autophagy pathways and provides mechanistic insights into metabolic dysfunction. Understanding CB1 receptor turnover may inform therapeutic strategies for obesity and metabolic disorders where the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) plays a central role. Clinical Summary This laboratory study used mouse models to investigate the relationship between autophagy receptor p62, CB1 receptor degradation, and metabolic phenotypes. Researchers found that CB1 receptors undergo autophagy-dependent degradation in neurons, and that p62-deficient mice develop late-onset obesity with elevated hypothalamic endocannabinoid levels but without increased food intake. The study suggests CB1 receptor signaling changes may contribute to metabolic dysfunction through altered energy expenditure rather than appetite regulation. Dr. Caplan’s Take “This adds important mechanistic detail to our understanding of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) regulation, though it’s purely preclinical work. The finding that obesity can occur without hyperphagia in this model reinforces that metabolic effects of cannabinoids extend well beyond [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/).” Clinical Perspective 🧠 While this research doesn’t directly change clinical practice, it supports the rationale for considering CB1 antagonists or modulators in metabolic medicine. Clinicians should continue to recognize that cannabis effects on metabolism involve complex pathways beyond simple [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/), particularly when counseling patients about weight management. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Exploring%20cannabinoid%20receptor%20CB1%20autophagy%20and%20the%20obesity%20phenotype%20of%20p62-de...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/42004545/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/42004545/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Exploring%20cannabinoid%20receptor%20CB1%20autophagy%20and%20the%20obesity%20phenotype%20of%20p62-de...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/42004545/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/42004545/](https://pubmed.ncbi.nlm.nih.gov/42004545/) Table of Contents - [FAQ](#FAQ)[How does autophagy affect CB1 receptor function in the brain?](#How_does_autophagy_affect_CB1_receptor_function_in_the_brain) - [Can defects in autophagy proteins like p62 contribute to obesity development?](#Can_defects_in_autophagy_proteins_like_p62_contribute_to_obesity_development) - [Does p62 deficiency directly affect CB1 receptor levels in metabolically relevant brain regions?](#Does_p62_deficiency_directly_affect_CB1_receptor_levels_in_metabolically_relevant_brain_regions) - [What role do endocannabinoids play in obesity associated with autophagy dysfunction?](#What_role_do_endocannabinoids_play_in_obesity_associated_with_autophagy_dysfunction) - [Are there clinical implications for targeting CB1 receptors in metabolic disorders involving autophagy?](#Are_there_clinical_implications_for_targeting_CB1_receptors_in_metabolic_disorders_involving_autophagy) - [Related](#Related) ## FAQ #### How does autophagy affect CB1 receptor function in the brain? This study demonstrates that CB1 receptors are subject to autophagy-dependent degradation, as blocking autophagy led to substantial CB1 receptor accumulation in neurons. Interestingly, CB1 receptor activation partially reduced this accumulation, suggesting that receptor stimulation influences its own turnover through autophagy pathways. #### Can defects in autophagy proteins like p62 contribute to obesity development? Yes, mice lacking the autophagy receptor p62 developed late-onset obesity without increased food intake, suggesting metabolic dysfunction rather than overeating as the cause. These mice also showed early hypoactivity and elevated levels of the endocannabinoid 2-AG in the hypothalamus, indicating disrupted energy metabolism regulation. #### Does p62 deficiency directly affect CB1 receptor levels in metabolically relevant brain regions? Surprisingly, p62 deficiency did not significantly alter CB1 receptor protein abundance in the brain or hypothalamus despite p62’s role in autophagy. However, the signaling downstream of CB1 receptors (ERK1/2 pathway) was modestly reduced in the hypothalamus, suggesting functional rather than quantitative changes. #### What role do endocannabinoids play in obesity associated with autophagy dysfunction? The study found elevated hypothalamic 2-arachidonoylglycerol (2-AG) levels in p62-deficient obese mice, indicating dysregulated endocannabinoid signaling. This suggests that autophagy dysfunction may contribute to obesity partly through alterations in endocannabinoid system activity, particularly in brain regions controlling metabolism. #### Are there clinical implications for targeting CB1 receptors in metabolic disorders involving autophagy? While this preclinical research shows interesting connections between autophagy, CB1 receptors, and metabolism, the clinical relevance remains in early stages requiring further evidence. The findings suggest that therapies targeting CB1 receptors might need to consider autophagy status, but human studies are needed to validate these mechanistic insights. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.](https://cedclinic.com/cbd-appetite-effects-increased-food-intake-clinical-study/) Explore how cannabidiol influences energy intake and metabolism in healthy adults, providing clinical insights relevant to metabolic regulation. [Read Study](https://cedclinic.com/cbd-appetite-effects-increased-food-intake-clinical-study/) [Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Learn about emerging research on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) and their potential therapeutic effects on [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) and metabolic health. [Learn More](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) Review current evidence on [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments in Europe, highlighting clinical relevance and patient care considerations. [Explore Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).